Cargando…
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC),...
Autores principales: | Bahmad, Hisham F., Demus, Timothy, Moubarak, Maya M., Daher, Darine, Alvarez Moreno, Juan Carlos, Polit, Francesca, Lopez, Olga, Merhe, Ali, Abou-Kheir, Wassim, Nieder, Alan M., Poppiti, Robert, Omarzai, Yumna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883996/ https://www.ncbi.nlm.nih.gov/pubmed/35225948 http://dx.doi.org/10.3390/medsci10010015 |
Ejemplares similares
-
Epithelial-to-Mesenchymal Transition-Related Markers in Prostate Cancer: From Bench to Bedside
por: Gogola, Samantha, et al.
Publicado: (2023) -
Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems
por: Doumat, George, et al.
Publicado: (2023) -
Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer
por: Gogola, Samantha, et al.
Publicado: (2023) -
The Use of Stem Cell-Derived Organoids in Disease Modeling: An Update
por: Azar, Joseph, et al.
Publicado: (2021) -
Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
por: El Zarif, Talal, et al.
Publicado: (2022)